Skip to main content

RIGEL PHARMACEUTICALS INC

For the period ended Dec 31, 2025. Filed Mar 3, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 3, 2026

RIGL$43.91+4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on March 3, 2026.

Rigel Pharmaceuticals, Inc.
By:/s/ RAUL R. RODRIGUEZ
Raul R. RodriguezChief Executive Officer (Principal Executive Officer)
By:/s/ DEAN L. SCHORNO
Dean L. SchornoChief Financial Officer (Principal Financial Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Raul R. Rodriguez and Dean L. Schorno, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

SignatureTitleDate
/s/ RAUL R. RODRIGUEZChief Executive Officer and DirectorMarch 3, 2026
Raul R. Rodriguez(Principal Executive Officer)
/s/ DEAN L. SCHORNOChief Financial OfficerMarch 3, 2026
Dean L. Schorno(Principal Financial Officer)
/s/ GREGG LAPOINTEChairman of the BoardMarch 3, 2026
Gregg Lapointe
/s/ KAMIL ALI-JACKSONDirectorMarch 3, 2026
Kamil Ali-Jackson
/s/ MARK W. FROHLICHDirectorMarch 3, 2026
Mark W. Frohlich
/s/ ALISON L. HANNAHDirectorMarch 3, 2026
Alison L. Hannah
/s/ MICHAEL P. MILLERDirectorMarch 3, 2026
Michael P. Miller
/s/ WALTER H. MOOSDirectorMarch 3, 2026
Walter H. Moos
/s/ JANE WASMANDirectorMarch 3, 2026
Jane Wasman
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.